Skip to content

Evaluation of Genetic Abnormalities Amongst Calcium Phosphate Stone Formers

Evaluation of Genetic Abnormalities Amongst Calcium Phosphate Predominant Stone Formers With Alkaline Urine pH on 24 Hour Urine Testing

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06974357
Enrollment
15
Registered
2025-05-15
Start date
2025-03-15
Completion date
2027-03-01
Last updated
2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithiasis

Keywords

Urolithiasis, Calcium Phosphates, Genetics, Urine

Brief summary

Kidney stones continue to affect more and more people in the United States with the most recent estimate being 1 in 9 people will develop a stone in their life. While family history is a known risk factor for stone disease, it remains unclear whether this is related to learned dietary habits or a truly inheritable genetic condition. Known inheritable genetic conditions linked to stone formation are uncommon, and thus, routine genetic testing is not currently recommended by any major urologic organizations. Patients who form calcium phosphate predominant stones, a less common type of stone composition, tend to have alkaline urine pH which suggests that the kidneys are unable to rid the body of acid. Management of such patients for stone prevention can be difficult. The Iowa Institute for Human Genomics is one of only a handful of commercial labs which offers genetic testing for stone disease. The aim of this study is to assess the rate of genetic abnormalities amongst calcium phosphate predominant stone formers with alkaline urine. To this end, the investigators plan to enroll calcium phosphate predominant stone forming patients with alkaline urine on 24 hour urine collection who obtain their health care at UIHC to undergo free genetic testing via blood draw to assess for genetic abnormalities. The investigators will also collect information already available in the subject's chart to assess for other patterns between blood and urine tests and any genetic variants.

Interventions

DIAGNOSTIC_TESTGenetic testing

blood draws for genetic testing

Sponsors

Ryan L Steinberg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Any patient, aged 18-90 and not incarcerated, under the care of a urologist at UIHC with known kidney stone composition including \>=60% calcium phosphate and baseline 24 hour urine pH of \>=6.3

Exclusion criteria

\- Any patient over the age of 90 years old, incarcerated or without any evidence of calcium phosphate stone composition * No struvite component on prior stone analysis * No bacteria with urease producing organism at time of stone removal * No history or evidence of systemic acidosis * No use of acetazolamide, topiramate, zonisamide, valproic acid * Stage \>=3 CKD (GFR\<60) * Hepatic disease * Pregnancy * History of osteoporosis

Design outcomes

Primary

MeasureTime frameDescription
Rate of genetic variants1 yearassess the overall rate of genetic variants among the stone population

Countries

United States

Contacts

Primary ContactRyan Steinberg, MD
ryan-steinberg@uiowa.edu3196787089

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026